About Ruemu Birhiray

Ruemu Birhiray, MD

About Ruemu Birhiray

Before joining Hematology Oncology of Indiana in July 2001, Dr. Birhiray worked as a medical oncologist at Marshfield Cancer Center in Wisconsin, where he also served as the director of the bone marrow transplant program. He earned his Doctor of Medicine degree from the University of Benin in Nigeria and went on to complete his internal medicine residency at Columbus Hospital in Chicago, an affiliate of Northwestern University. His specialized training includes fellowships in bone marrow transplantation at Johns Hopkins University and medical oncology at the National Cancer Institute in Bethesda, Maryland.

Dr. Birhiray has contributed to the field through research and publications focusing on immunotherapy, lymphomas, and bone marrow transplantation. He is an active member of several professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, the American Medical Association, and the Wisconsin Medical Society.

Articles by Ruemu Birhiray, MD

Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
An expert panel discusses utilizing molecular strategies to determine treatment decisions for DLBCL.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
In this DLBCL roundtable, experts share which novel agents or combinations they are most interested in.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
Ruemu Birhiray, MD, leads an expert roundtable on the current treatment pathway in DLBCL.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
The expert panel assesses the current and expected utility for clinicians of MRD in DLBCL management decisions.
Ruemu Birhiray, MDFollicular Lymphoma | March 4, 2025
With insights into next-generation therapies, this discussion explores what’s ahead in the follicular lymphoma landscape.
Ruemu Birhiray, MDFollicular Lymphoma | March 4, 2025
Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on FL treatment.
Ruemu Birhiray, MDFollicular Lymphoma | March 4, 2025
Three experts analyze data on combination therapy for FL, including efficacy, safety, and strategy adoption.